title: Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
abstract: OBJECTIVE
  Studies of the effect of thyroxine therapy on skeletal integrity have given conflicting results; the reductions in bone mass reported by some have prompted recommendations that the prescribed replacement doses of thyroxine should be reduced. We have examined bone mineral density in a group of patients with differentiated thyroid carcinoma receiving high doses of thyroxine to suppress thyroid stimulating hormone (TSH).
  
  
  METHODS
  The 44 patients (6 male, 38 female) had a median age of 49 years (range 27-75) with median duration of thyroxine therapy of 9.0 years (range 3 to 42) and mean dose of thyroxine 0.167 mg/day (range 0.125-0.3). TSH levels were chronically suppressed in 39 subjects. Bone mineral density (BMD) was measured by dual energy x-ray absorptiometry (DEXA) in all subjects at the femoral neck and lumbar spine and compared with previously established local reference ranges.
  
  
  RESULTS
  There was no reduction in bone mineral density in the thyroxine treated group compared with the local reference population at both lumbar spine and femoral neck, and no correlation with duration of therapy.
  
  
  CONCLUSIONS
  These negative findings, that thyroxine in suppressive doses does not significantly reduce bone mineral density in New Zealand patients suggest that thyroxine therapy alone is not a major risk factor for the development of osteoporosis.
authors.affiliation: Department of Endocrinology, Christchurch Hospital.
authors.forename: C M
authors.initials: CM
authors.lastname: Florkowski
authors.forename: B E
authors.initials: BE
authors.lastname: Brownlie
authors.forename: J R
authors.initials: JR
authors.lastname: Elliot
authors.forename: E M
authors.initials: EM
authors.lastname: Ayling
authors.forename: J G
authors.initials: JG
authors.lastname: Turner
mesh_terms: D015502:Absorptiometry, Photon; D018263:Adenocarcinoma, Follicular / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D000367:Age Factors; D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D002291:Carcinoma, Papillary / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D016022:Case-Control Studies; D005260:Female; D005272:Femur Neck / Q000000981:diagnostic imaging; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology*; D011877:Radionuclide Imaging; D012016:Reference Values; D012307:Risk Factors; D013964:Thyroid Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D013972:Thyrotropin; D013974:Thyroxine